Harpoon therapeutics, inc. (HARP)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities
Net loss

-54,545

-55,572

-51,035

-41,887

-36,064

-27,366

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense

2,549

2,071

1,639

1,221

894

672

0

0

0

Depreciation and amortization

1,106

900

597

952

802

644

0

0

0

Non cash lease expense

1,012

1,202

0

0

0

-

-

-

-

Net amortization of discounts on marketable securities

0

-

-

-

0

-

-

-

-

Changes in operating assets and liabilities
Accounts receivable

-

-

-

-

-

-

-

-

0

Prepaid expenses and other assets

3,519

1,814

688

2,452

1,736

507

0

0

0

Other assets

-85

-3,042

0

0

0

-

-

-

-

Accounts payable

-2,080

-1,761

1,868

1,711

2,293

2,555

0

0

0

Accrued liabilities

3,392

4,288

5,273

1,797

1,730

1,048

0

0

0

Deferred revenue

10,688

6,957

-4,604

-4,250

-4,250

-4,250

0

0

0

Operating lease liabilities

-437

-15

0

0

0

-

-

-

-

Deferred revenue, non current

0

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

78

0

0

0

Net cash used in operating activities

-7,983

-2,891

-43,053

-38,918

-32,410

-27,126

0

0

0

Cash flows from investing activities
Purchases of property and equipment

3,449

3,516

3,304

1,741

643

663

0

0

0

Purchases of marketable securities

136,742

141,816

0

0

0

-

-

-

-

Maturities of marketable securities

0

-

-

-

-

-

-

-

-

Net cash used in investing activities

-52,982

-69,315

-67,201

-83,200

-52,220

-663

0

0

0

Cash flows from financing activities
Proceeds from initial public offering of common stock, net of commissions

-

70,646

0

0

0

-

-

-

-

Deferred offering costs

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon exercise of stock options, net

1,109

803

301

287

182

158

0

0

0

Net cash provided by financing activities

1,207

71,449

139,160

159,119

158,823

88,326

0

0

0

Net increase (decrease) in cash, cash equivalents, and restricted cash

-59,758

-757

28,906

37,001

74,193

60,537

0

0

0

Supplemental disclosures of non-cash investing and financing information
Conversion of preferred stock to common stock and additional paid-in capital

-

129,577

0

0

0

-

-

-

-

Purchases of property and equipment included in accrued liabilities

83

16

151

2,161

-159

28

0

0

0

Reclassification of employee stock liability to equity upon vesting

0

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued liabilities

0

-

-

-

-

-

-

-

-

Right-of-use asset obtained in exchange for lease obligation

-

8,405

0

0

0

-

-

-

-

Tenant improvements provided by landlord

-

5,784

0

0

0

-

-

-

-

Initial public offering costs included in accounts payable

-

-

-

-

0

-

-

-

-